Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy

Related Experiment Video

Updated: May 25, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

S Nowsheen1, A C Whitley, E S Yang

  • 1Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, 176F HSROC Suite 2232B, 1700 6th Avenue South, Birmingham, AL 35249-6832, USA.

Current Molecular Medicine
|February 2, 2012
PubMed

Insights

Targeting DNA repair pathways can enhance cancer therapy. Novel biomarkers are crucial for personalized medicine, assessing tumor response and improving patient outcomes in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Tumor cells can survive DNA damage by hyper-activating DNA repair pathways.
  • Targeting these pathways presents a promising strategy for cancer therapy.
  • Personalized therapy requires reliable biomarkers to predict treatment response.

Purpose of the Study:

  • To review DNA repair machinery as a therapeutic target in cancer.
  • To discuss DNA damage and repair biomarkers for cancer prognosis.
  • To explore the application of biomarkers in assessing therapy response for improved patient care.

Main Methods:

  • Literature review focusing on DNA repair mechanisms in cancer.
  • Analysis of existing research on DNA repair inhibitors and biomarkers.
  • Synthesis of information on biomarker utility in personalized cancer treatment.

Main Results:

  • DNA repair pathways are critical for tumor cell survival and therapeutic resistance.
  • Specific DNA repair pathways represent viable targets for novel cancer therapies.
  • Biomarkers associated with DNA damage and repair can predict prognosis and guide treatment decisions.

Conclusions:

  • Targeting DNA repair pathways offers a promising avenue for enhancing cancer treatment efficacy.
  • Biomarkers are essential for tailoring therapies and monitoring treatment response in oncology.
  • Integrating biomarker analysis into treatment design can optimize patient outcomes and quality of life.

More Related Videos

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...